Scope and Claims Analysis for US Patent 6,303,661 (DP‑IV Inhibitors for Food-Intake Post‑Prandial Hyperglycemia)
US 6,303,661 claims a method of lowering elevated blood glucose in mammals attributable to food intake using oral administration of DP‑IV inhibitors, with dependent claim scope narrowing to specific small-molecule inhibitors (alanyl pyrrolidine, isoleucyl thiazolidine, N‑valyl prolyl, O‑benzoyl hydroxylamine) and dosing/administration modalities (carriers, multiple administrations, 1–10 mg/kg).
What is the scope of US 6,303,661 and how broad are the independent method claims?
Featured snippet answer: The independent claim covers any method lowering food-intake-related elevated blood glucose by orally administering a therapeutically effective amount of at least one inhibitor of DP‑IV or DP‑IV-like enzyme activity.
Independent claim coverage (Claim 1)
Claim 1 is a classic composition-for-use-to-therapy method framework:
- Act: “administering at least one oral administration” (read as oral administration of a DP‑IV inhibitor)
- Mechanistic requirement: “at least one inhibitor of Dipeptidyl Peptidase (DP IV) or of DP IV-like enzyme activity”
- Therapeutic target: “lowering elevated blood glucose levels in mammals resulting from food intake”
- Dose/level: “therapeutically effective amount” (no unit limits required by Claim 1)
- Induced condition context: the claim is specifically tied to food intake resulting hyperglycemia (post-prandial component)
Practical scope notes
- Mechanism breadth: “DP‑IV-like enzyme activity” expands beyond canonical DPP‑4 where an accused compound/inhibitor plausibly inhibits a functionally equivalent dipeptidyl peptidase relevant to incretin biology.
- Use boundary: by requiring hyperglycemia “resulting from food intake,” the claim is not limited to fasting glucose lowering, though it would still likely read on post-prandial and mixed basal/post-prandial abnormalities.
- Formulation neutrality: Claim 1 does not require a specific formulation type, carrier, or excipient system.
Claim 1 does not require
- Diabetes diagnosis, severity, or specific endpoints beyond lowering elevated blood glucose.
- Specific inhibitor identity.
- Specific dose range (that is introduced later in dependent Claim 5).
What DP‑IV inhibitors are expressly claimed in dependent claims and what does that do to infringement risk?
Featured snippet answer: Dependent claims pick specific DP‑IV inhibitor candidates and convert “DP‑IV inhibitor” into a narrower list, which can increase validity and enforceability for those named actives while leaving a broader halo for other DP‑IV-like inhibitors under Claim 1.
Specific inhibitors listed (Claim 2, Claim 9)
Claim 2 depends on Claim 1 and specifies:
- alanyl pyrrolidine
- isoleucyl thiazolidine
- N‑valyl prolyl, O‑benzoyl hydroxylamine
Claim 8 and Claim 9 add further specificity:
- Claim 8: isoleucyl thiazolidine
- Claim 9: alanyl pyrrolidine and isoleucyl thiazolidine (selected from group)
Infringement and scope implications
- If a competitor uses one of the named actives in an accused oral regimen that targets food-intake-related elevated glucose, it can fall under multiple claims simultaneously (Claim 1 plus the corresponding dependent claim).
- If a competitor uses a different DP‑IV inhibitor not named in dependent claims:
- It can still infringe Claim 1 if it is proven to be an “inhibitor of DP‑IV or DP‑IV-like enzyme activity.”
- The language gives Claim 1 a broader target, while dependent claims provide a tighter “hook” for named compounds.
How do the dosing and administration limitations (Claims 3–6) constrain the claim set?
Featured snippet answer: Dependent claims impose additional boundaries on formulation (carrier), regimen (multiple administrations), and dosage (1.0 to 10.0 mg/kg) and introduce clinical context tied to basal and post-prandial hyperglycemia and metabolic pathology.
Carrier and regimen
- Claim 3: administration “in combination with at least one carrier substance”
- This adds a formulation limitation only for that dependent claim. It does not narrow Claim 1 unless the carrier is also required in the independent claim analysis.
- Claim 4: “administered in multiple administrations”
- This limits that dependent claim to split or repeated dosing schedules.
- If a competitor uses once-daily dosing rather than multiple administrations, they might avoid Claim 4 but still potentially land in Claim 1 if all other elements are met.
Dose window
- Claim 5: “amount is between 1.0 mg to 10.0 mg per kilogram”
- This is a material narrowing limitation.
- It matters most for enforcement when the accused product uses a different dose range (or uses mg per unit rather than per kg in label; actual dosing in practice controls).
Clinical phenotype and disease-state language
- Claim 6: mammals demonstrate “clinically inappropriate basal and post-prandial hyperglycemia”
- Claim 7: for prevention or alleviation of pathological metabolic abnormalities, including:
- glucosuria
- hyperlipidaemia
- metabolic acidosis
- Diabetes mellitus
Enforcement impact
- Claims 6 and 7 create a disease-state tether. If an accused regimen is aimed at a non-disease-specific metabolic endpoint, Claim 6/7 may be harder to prove even if Claim 1 covers the mechanism and immediate post-prandial effect.
What is the required “food intake resulting hyperglycemia” element and how can it be satisfied?
Featured snippet answer: The claims require blood glucose elevation causally linked to food intake; oral administration of a DP‑IV inhibitor to lower those post-prandial glucose excursions aligns well with incretin-mediated mechanisms.
Causation boundary
- The phrase “resulting from food intake” is an element that can be evaluated through:
- clinical endpoints like post-prandial glucose AUC or peak glucose after meals
- experimental challenge designs (meal tolerance tests, standardized feeding studies)
Practical reading
- A regimen that shows efficacy in post-prandial glucose suppression after oral dosing would be directly aligned.
- Trials focused exclusively on fasting glucose lowering would have a weaker fit with the “resulting from food intake” limitation, unless evidence shows the treatment also changes food-triggered hyperglycemia.
What is the breadth of “DP IV-like enzyme activity” and how does it affect the patent landscape?
Featured snippet answer: “DP IV-like enzyme activity” broadens coverage beyond DPP‑4 to functional equivalents, increasing the chance of claim capture for next-generation inhibitors with overlapping substrate specificity.
Why “DP‑IV-like” matters
- Many peptidases have dipeptidyl aminopeptidase activity profiles. A compound can be argued to inhibit DP‑IV-like enzymatic activity relevant to incretin degradation.
- Under Claim 1, proof typically centers on:
- biochemical inhibition data (IC50 against DP‑IV and related enzymes)
- functional assays showing incretin preservation and downstream glucose lowering
Landscape consequence
- In patent disputes involving DPP‑4 inhibitors, this language can reduce the “label mismatch” defense for mechanistically overlapping compounds that may not be marketed as classic DPP‑4 inhibitors but show DP‑IV-like activity.
How does the claim set compare with later DPP‑4 inhibitor patent families (class-level versus drug-specific coverage)?
Featured snippet answer: US 6,303,661 is class-method centric: it claims a mechanistic method tied to DP‑IV inhibition and oral administration, rather than a specific molecule with a specific formulation.
Where this patent sits in the typical evolution
- Early DPP‑4 inhibitor intellectual property often uses:
- broad method claims for post-prandial glucose lowering
- inhibitor class identifiers (DP‑IV, DP‑IV-like)
- oral administration requirements
- Later families tend to carve out:
- specific scaffolds with defined substituents
- formulation patents (immediate-release, controlled release, combinations)
- method-of-use refinement (patient subsets, comorbidities, dosing schedules)
Net effect for freedom-to-operate
- Any oral DPP‑4 inhibitor program in the same therapeutic context historically faces:
- method claim exposure if the competitive product is a DP‑IV inhibitor used for post-prandial glucose lowering
- narrower carve-outs only if the competitor avoids key claim elements like “food intake resulting hyperglycemia,” “oral,” or the required active mechanism
What claims are likely to be strongest for enforcement versus the weakest hooks?
Featured snippet answer: The strongest hooks are Claim 1 (DP‑IV/DP‑IV-like inhibitor, oral, food-intake hyperglycemia lowering) and dependent claims naming specific inhibitors. The weakest hooks are those requiring a specific dose window or particular clinical-state language.
Strength ranking (within the provided claim set)
- Claim 1 (broad, mechanistic, oral, meal-linked hyperglycemia)
- Claims 8–9 and 2 (named inhibitors)
- Claim 3 (carrier combination)
- Claim 4 (multiple administrations)
- Claim 5 (1.0–10 mg/kg)
- Claims 6–7 (clinically inappropriate basal+post-prandial hyperglycemia; prevention/alleviation with specific metabolic abnormalities)
Why this ranking holds
- Proof burden increases when claims add:
- dosing thresholds
- clinical phenotype definitions
- prevention/alleviation endpoint lists
How many distinct “infringement pathways” do these claims create? (Claim chart structure)
Featured snippet answer: The claim set creates multiple independent entry points: mechanism-based (DP‑IV/DP‑IV-like) plus optional narrowing dimensions (named inhibitors, carrier, multiple dosing, mg/kg range, disease phenotype).
Minimum element set (to map likely infringement)
A competitor’s regimen likely needs:
- Mammal
- Oral administration
- DP‑IV or DP‑IV-like inhibitor
- Therapeutically effective amount (explicit dose only for Claim 5)
- Lowering elevated blood glucose “resulting from food intake”
Optional narrowing elements (dependent claims)
- Use of one of the named inhibitors
- Co-administration with carrier
- Multiple dosing events
- Dose between 1.0 and 10.0 mg/kg
- Clinically inappropriate basal+post-prandial hyperglycemia
- Prevention/alleviation of glucosuria/hyperlipidemia/metabolic acidosis/diabetes mellitus
What patent landscape questions can be answered from the claim language alone?
Featured snippet answer: Yes for scope and coverage; no for expiration, Orange Book status, or litigation timeline without external records. The provided claim text supports only IP scope analysis and not regulatory or event-based facts.
Patent scope questions answerable from claims
- What therapeutic context is covered? Food-intake-related elevated blood glucose in mammals.
- What mechanism is covered? DP‑IV inhibition and DP‑IV-like enzymatic activity inhibition.
- What administration route is covered? Oral.
- What inhibitor identities are expressly named? alanyl pyrrolidine, isoleucyl thiazolidine, N‑valyl prolyl, O‑benzoyl hydroxylamine.
- What regimen aspects are limited? carrier combination and multiple administrations.
- What dosing window is limited? 1.0–10 mg/kg.
- What disease-state framing is included? diabetes mellitus and related metabolic abnormalities.
Patent landscape questions not answerable from claims alone
The following require patent bibliographic and prosecution data plus FDA and Orange Book and litigation docket review:
- expiration dates
- family members and continuations
- whether the patent is listed for any NDA/ANDA
- whether any Paragraph IV challenges were filed
- whether settlements occurred
- whether biosimilars are relevant (this appears small-molecule method claims, not biologics)
Key Takeaways
- US 6,303,661 is a broad method-of-treatment patent focused on oral DP‑IV inhibition to lower food-intake-related elevated blood glucose in mammals.
- Claim 1 provides the primary sweep: any DP‑IV or DP‑IV-like inhibitor that lowers meal-linked hyperglycemia can fit.
- Dependent claims narrow the field by naming specific inhibitors (alanyl pyrrolidine; isoleucyl thiazolidine; N‑valyl prolyl, O‑benzoyl hydroxylamine) and by adding optional limitations on carriers, multiple dosing, 1.0–10 mg/kg, and specific metabolic/diabetes endpoint framing.
- For competitive risk assessment, the key mapping task is whether an accused oral regimen using a DP‑IV(-like) inhibitor produces measured reductions in post-prandial or meal-triggered hyperglycemia.
FAQs
-
Does the claim require post-prandial data or is fasting glucose also covered?
The language requires hyperglycemia “resulting from food intake,” which aligns most directly with post-prandial or meal challenge outcomes rather than fasting-only effects.
-
Can a compound that inhibits DP‑IV-like enzymes but is not labeled as a DPP‑4 inhibitor infringe Claim 1?
Yes in principle, because Claim 1 covers inhibitors of DP‑IV or DP‑IV-like enzyme activity.
-
If an accused drug uses a dose outside 1.0–10 mg/kg, does it avoid infringement entirely?
It may avoid dependent Claim 5, but it can still fall under Claim 1 if “therapeutically effective amount” and other elements are met.
-
Is a carrier substance mandatory for infringement?
No for Claim 1; carrier is only required for dependent Claim 3.
-
If dosing is once daily rather than multiple administrations, does that avoid the patent?
It can avoid dependent Claim 4, but Claim 1 may still apply depending on the overall oral administration and efficacy elements.
References
No external sources were cited.
